Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19

NEXT STORY
Laidlaw Venture Partners Continues Strategic Growth with Addition of Paul Korner, MD, MBA and Tony N. Hodges MD FCCP FACP, to its Investment and Operations Committee
PREV STORY
Global Microbial Identification Market (2020 to 2025) – Bioterrorism Surveillance Presents Opportunities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

38% Objective Response Rate (ORR) demonstrated in 47 Metastatic Melanoma patients who were unsuccessfully ...

author_avatar
NASDAQ Market News

OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer

author_avatar
NASDAQ Market News

atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data

author_avatar
NASDAQ Market News